Nicoletta Colombo
Overview
Explore the profile of Nicoletta Colombo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
310
Citations
11124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Riva C, Minetto P, Chies M, Vernarecci C, Colombo N, Rosellini S, et al.
Hematol Oncol
. 2024 Dec;
43(1):e70005.
PMID: 39635952
Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventional...
12.
Valenza C, Nicolo E, Mongillo M, Trapani D, Katrini J, Boldrini L, et al.
Oncologist
. 2024 Nov;
PMID: 39607864
Background: Patients with a germline BRCA pathogenic variant (gBRCA-PV) and advanced high grade ovarian carcinoma (aHGOC) experience higher hematologic adverse events (HAEs) when receiving platinum salts and ionizing radiations, compared...
13.
Biagioli E, Rulli E, Fossati R, Colombo N
Lancet Oncol
. 2024 Oct;
25(11):e536.
PMID: 39481406
No abstract available.
14.
Moore K, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, et al.
Gynecol Oncol
. 2024 Oct;
191:249-258.
PMID: 39461270
Objective: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor alpha (FRα), which is overexpressed in epithelial ovarian cancer (EOC), with limited expression on normal tissues. This integrated...
15.
Haggstrom L, Lee Y, Scott C, Harter P, Woelber L, Ledermann J, et al.
Int J Gynecol Cancer
. 2024 Oct;
34(12):1932-1939.
PMID: 39438068
Objective: There are no data, and thus no consensus, on the optimal duration of poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy for exceptional responders (here defined as progression-free for 5 years...
16.
McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, et al.
Lancet
. 2024 Oct;
404(10462):1525-1535.
PMID: 39419054
Background: Locally advanced cervical cancer is treated with chemoradiotherapy (standard of care), but many patients still relapse and die from metastatic disease. We investigated chemoradiotherapy with or without induction chemotherapy...
17.
Golia DAuge T, Caruso G, Laudani M, Nazzaro L, De Vitis L, Rosanu N, et al.
Int J Gynecol Cancer
. 2024 Oct;
34(12):1867-1873.
PMID: 39379329
Objective: The standard treatment for early-stage cervical cancer includes radical hysterectomy with pelvic lymph node staging ± bilateral salpingo-oophorectomy. Para-aortic lymphadenectomy may be considered; however, its role remains controversial. The...
18.
Grisham R, Monk B, Van Nieuwenhuysen E, Moore K, Fabbro M, OMalley D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375168
Background: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with...
19.
Caruso G, Langstraat C, Kumar A, McGree M, Fought A, Nasioudis D, et al.
Gynecol Oncol
. 2024 Oct;
191:86-94.
PMID: 39366034
Objective: Textbook oncologic outcome (TOO) has been validated in surgical oncology as a composite quality measure correlated with oncologic outcomes. We aimed to assess the association between TOO and overall...
20.
Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, et al.
Int J Gynecol Cancer
. 2024 Sep;
34(12):1914-1923.
PMID: 39322609
Objective: The aim of this study was to investigate the association of co-medication with metformin, a statin, or beta blocker with survival in patients with primary ovarian cancer. Methods: Individual...